- Current report filing (8-K)
November 04 2010 - 4:05PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
November 4,
2010
ALLOS THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
000-29815
|
|
54-1655029
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
11080 CirclePoint Road, Suite 200
Westminster, Colorado
|
|
80020
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrants
telephone number, including area code:
(303)
426-6262
Not applicable
(Former
name or former address, if changed since last report.)
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Section 2
|
|
Financial Information
|
|
|
|
Item 2.02
|
|
Results of Operations and Financial Condition.
|
On
November 4, 2010, Allos Therapeutics, Inc., a Delaware corporation,
issued a press release reporting its financial results for the quarter and nine
months ended September 30, 2010. The press release is attached hereto
as Exhibit 99.1, which is furnished under Item 2.02 of this report and
shall not be deemed to be filed for purposes of Section 18 of the
Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to
the liabilities of that section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933 or the Exchange Act,
regardless of any general incorporation language in such filing.
Section 9
|
|
Financial Statements and Exhibits
|
Item 9.01 Financial Statements and Exhibits.
(d)
|
|
Exhibits.
|
|
|
|
99.1
|
|
Press Release, dated November 4, 2010, entitled Allos Therapeutics Reports Third Quarter
2010 Financial Results.
|
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: November 4,
2010
|
|
|
|
|
|
|
|
ALLOS
THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/
David C. Clark
|
|
|
David
C. Clark
|
|
Its:
|
Vice
President, Finance and Treasurer
|
3
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press
Release, dated November 4, 2010, entitled Allos Therapeutics Reports Third Quarter 2010 Financial Results.
|
4
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From May 2024 to Jun 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jun 2023 to Jun 2024